Purpose

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Conditions

Eligibility

Eligible Ages
All ages
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment. - 2. Participant has plans for future visits at the site for continued management of IMISC.

Exclusion Criteria

  • 1. Inability to provide written informed consent/assent. - 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Other

Recruiting Locations

Johnson Dermatology
Fort Smith, Arkansas 72916
Contact:
Crystal Marrazzo
479-649-3376
study@johnsondermatology.com

Arkansas Dermatology
Little Rock, Arkansas 72223
Contact:
Heather Meins, RN, BSN
501-412-0923
hsadler23@yahoo.com

First OC Dermatology
Fountain Valley, California 92708
Contact:
Cindy Nguyen
714-531-2966
registries.firstocdermatology@gmail.com

University of California
Irvine, California 92697
Contact:
Melissa Orr
949-824-2319
orrma@uci.edu

University of California - San Diego/Rady Children's Hospital
San Diego, California 92123
Contact:
Caitlyn Kellogg
858-576-1700
caitlynckellogg@gmail.com

George Washington University
Washington, District of Columbia 20037
Contact:
Radwa Aly
202-741-2437
raly@mfa.gwu.edu

Lurie Children's Hospital/Northwestern University
Chicago, Illinois 60611
Contact:
Dermatology CTU
312-503-5944
NUderm-research@northwestern.edu

Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group
Indianapolis, Indiana 46520
Contact:
Ashley N Wallace
317-516-5030
awallace@ecommunity.com

The University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Caitlin McMillian
913-588-0681
cmcmillian@kumc.edu

Family Allergy and Asthma Research Institute
Louisville, Kentucky 40215
Contact:
James W Sublett, MD
502-368-0732
wsublett@familyallergy.com

DermAssociates, LCC
Rockville, Maryland 20850
Contact:
Benjamin Lockshin, MD
301-355-3183
blockshin@dermassociates.com

University of Minnesota
Minneapolis, Minnesota 55455
Contact:
Irmina Wallander
wall0396@umn.edu

Carl Thornblade, MD, PLLC
Missoula, Montana 59808
Contact:
Krystal Fagan
706-728-6472
Krystalh@drthornblade.com

Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire 03756
Contact:
Staci Shaw
603-650-3693
Staci.L.Shaw@Hitchcock.org

Windsor Dermatology
East Windsor, New Jersey 08520
Contact:
Elise Nelson
609-443-4500
enelson@windsordermatology.com

Montefiore Medical Center
Bronx, New York 10467
Contact:
Haley Heibel, MD
718-920-8352
hheibel@montefiore.org

Centurion Dermatology
Brooklyn, New York 11219
Contact:
Anna Yu
Centurionderm@gmail.com

Empire Dermatology
East Syracuse, New York 13057
Contact:
Jeffrey Cizenski, MD
315-500-7546
jcizenski@empirederamtology.com

Forest Hills Dermatology Group
Forest Hills, New York 11375
Contact:
Jeffrey Weinberg, MD
718-459-0900
jmw27@columbia.edu

Greenwich Village Dermatology
New York, New York 10012
Contact:
Jasmina Jeter
212-385-3700
jjeter@thedermspecs.com

Ichan School of Medicine
New York, New York 10029
Contact:
Ester Del Duca
917-969-4386
ester.delduca@mssm.edu

Allergy Partners of Western North Carolina
Asheville, North Carolina 28801
Contact:
David Cypcar, MD
828-348-7074
dmcypcar@allergypartners.com

UNC Dermatology
Chapel Hill, North Carolina 27516
Contact:
Daisy Hernandez
984-974-3682
daisy_hernandez@med.unc.edu

Wake Forest University Health Sciences
Winston-Salem, North Carolina 27157
Contact:
Irma Richardson
336-716-2903
irichard@wakehealth.edu

Ohio State University
Columbus, Ohio 43215
Contact:
Erin Frey
614-366-2025
erin.frey@osumc.edu

Oregon Health and Science University
Portland, Oregon 97239
Contact:
David Schlichting
503-418-1680
schlichd@ohsu.edu

Allergy and Clinical Immunology
Pittsburgh, Pennsylvania 15241
Contact:
Michael Palumbo, MD
412-833-4051
michael.palumbo.1994@owu.edu

The Medical University of South Carolina
Charleston, South Carolina 29425
Contact:
Courtney Rowley
843-792-9784
rowle@musc.edu

El Paso Dermatology Center
El Paso, Texas 79902
Contact:
Kassandra McCoy
915-544-3254
kassandra@epdermatology.com

Allergy Associates of Utah
Murray, Utah 84107
Contact:
Sandy Warr
801-263-8700
sandy.warr@utahallergies.com

University of Utah MidValley Dermatology
Murray, Utah 84107
Contact:
Adrianne Evans
801-213-0375
adrianne.evans@hsc.utah.edu

Virginia Commonwealth University
Richmond, Virginia 23219
Contact:
Kimberly Salkey, MD
804-560-8919
kimberly.salkey@vcuhealth.org

North Sound Dermatology
Mill Creek, Washington 98012
Contact:
Bhatki Rangole
425-275-4404
bhatki.rangole@frontierdermpartners.com

Children's Hospital of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Alexandria Cook
414-266-6165

More Details

NCT ID
NCT03661866
Status
Recruiting
Sponsor
Target PharmaSolutions, Inc.

Study Contact

Laura Dalfonso
9842340268
ldalfonso@targetrwe.com

Detailed Description

TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.